The Global Next-Generation Sequencing Market Size is Estimated to Grow at a CAGR of 18.96% by 2030, estimates DelveInsight

DelveInsight’s Next-Generation Sequencing Market Insights Report 2030 provides the current and forecast market analysis, individual leading Next-Generation Sequencing Companies market shares, challenges, Next-Generation Sequencing Market Drivers, barriers, trends, and key market Next-Generation Sequencing companies in the market.

To read more about the latest highlights related to the Next-Generation Sequencing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/next-generation-sequencing-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Next-Generation Sequencing Market Report

• In December 2021, Roche launched the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error, and advance precision medicine, marking a significant step forward in NGS workflow efficiency.
• In May 2021, Illumina, Inc. and Next-Generation Genomics Co., Ltd. launched VeriSeq™ NIPT Solution v2 in Thailand, a CE-IVD, NGS-based approach to noninvasive prenatal testing, expanding access to advanced genomic diagnostics in the Asia-Pacific region.
• In February 2021, INOVIO and QIAGEN expanded their collaboration to develop a next-generation sequencing companion diagnostic for INOVIO’s VGX-3100 for advanced cervical dysplasia, reflecting the growing integration of NGS into targeted therapy development.
• The global Next-Generation Sequencing market was valued at USD 9.28 billion in 2023, growing at a CAGR of 18.96% during the forecast period from 2024 to 2030 to reach USD 26.30 billion by 2030.
• North America is projected to hold the largest share of the Next-Generation Sequencing market during the forecast period, driven by several key factors.
• The leading Next-Generation Sequencing Companies such as Agilent Technologies, Inc., Illumina Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, PerkinElmer Inc., MedGenome, BGI, Pacific Biosciences, GENEWIZ, Oxford Nanopore Technologies plc., Psomagen, Inc., 10x Genomics, Takara Bio Inc., Zymo Research Corporation, NuGEN Technologies, Inc. (Tecan Trading AG), Vela Diagnostics, CD Genomics, HTG Molecular Diagnostics, Inc., and others.

To know more about why North America is leading the market growth in the Next-Generation Sequencing Market, get a snapshot @ Next-Generation Sequencing Market Outlook 

Next-Generation Sequencing Market Dynamics

The Next-Generation Sequencing market is experiencing robust growth driven by the escalating global burden of infectious diseases and cancer. According to WHO (December 2021), approximately 275 million confirmed COVID-19 cases were reported globally, with NGS technology playing a critical role in identifying novel viral strains and supporting pandemic surveillance — an application that significantly elevated awareness and adoption of NGS platforms in clinical settings. Simultaneously, the rising incidence of cancer is amplifying demand for NGS-based diagnostic tools. According to GLOBOCAN (2020), approximately 19.3 million new cancer cases were detected globally in 2020, driving growing reliance on NGS technology for cancer biomarker detection, companion diagnostics, and the development of precision medicine and personalized treatment approaches across the forecast period from 2024 to 2030.

Next-Generation Sequencing Market Segmentation Analysis

Next-Generation Sequencing Market by Product Type (Instruments, Reagents & Consumables, and Services), Sequencing Type (Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Targeted Sequencing, De-Novo Sequencing, and Others), Application (Diagnostic, Drug Discovery, Agriculture & Animal Research, and Others), End-User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, and Academic & Research Institutes), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the sequencing type segment of the Next-Generation Sequencing market, the Whole Genome Sequencing (WGS) category is anticipated to hold a significant market share during the forecast period. This is primarily because WGS provides the most comprehensive genomic data of any organism in a short duration of time and is extensively used to develop precision medicines and personalized treatment protocols. The growing focus of key market players on developing NGS-based whole genome sequencing panels for the detection of infectious disease agents — including the rapid development of COVID-19-targeted sequencing panels — further reinforces the dominance of this segment throughout the forecast period.

Get a sneak peek at the Next-Generation Sequencing Market Dynamics @ Next-Generation Sequencing Market Dynamics Analysis

Next-Generation Sequencing Market Key Players

Agilent Technologies, Inc., Illumina Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, PerkinElmer Inc., MedGenome, BGI, Pacific Biosciences, GENEWIZ, Oxford Nanopore Technologies plc., Psomagen, Inc., 10x Genomics, Takara Bio Inc., Zymo Research Corporation, NuGEN Technologies, Inc. (Tecan Trading AG), Vela Diagnostics, CD Genomics, HTG Molecular Diagnostics, Inc., and others.

Next-Generation Sequencing Market Drivers

The demand for Next-Generation Sequencing is primarily driven by the rising cases of infectious diseases — particularly the COVID-19 pandemic, which elevated the role of NGS as a cost-effective, high-throughput molecular diagnostic tool — and the escalating global burden of cancer, where NGS-based platforms are increasingly critical for biomarker detection, companion diagnostics, and targeted therapy selection. The rising application of NGS technology in clinical diagnosis and scientific research, along with its advantages of efficient turnaround times, high speed, and accuracy, are further propelling market expansion. Favorable reimbursement policies, increasing regulatory approvals for NGS-based diagnostic products, and growing R&D investments from both public and private sectors are collectively creating a robust and sustained growth environment for the Next-Generation Sequencing market throughout the forecast period from 2024 to 2030.

Which key players in the Next-Generation Sequencing Market are set to emerge as trendsetters? Explore @ Next-Generation Sequencing Companies

Scope of the Next-Generation Sequencing Market Report

• Coverage – Global
• Study Period – 2021–2030
• Forecast Period – 2024–2030
• Next-Generation Sequencing Companies – Agilent Technologies, Inc., Illumina Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., QIAGEN, Thermo Fisher Scientific, PerkinElmer Inc., MedGenome, BGI, Pacific Biosciences, GENEWIZ, Oxford Nanopore Technologies plc., Psomagen, Inc., 10x Genomics, Takara Bio Inc., Zymo Research Corporation, NuGEN Technologies, Inc. (Tecan Trading AG), Vela Diagnostics, CD Genomics, HTG Molecular Diagnostics, Inc., and others.

Interested in knowing the Next-Generation Sequencing Market by 2030? Click to get a snapshot of the Next-Generation Sequencing Market Trends – https://www.delveinsight.com/sample-request/next-generation-sequencing-market?utm_source=pngw&utm_medium=pr&utm_campaign=kkpr

Table of Contents

1. Next-Generation Sequencing Market Report Introduction
2. Next-Generation Sequencing Market Executive Summary
3. Regulatory and Patent Analysis
4. Next-Generation Sequencing Market Key Factors Analysis
5. Next-Generation Sequencing Porter’s Five Forces Analysis
6. COVID-19 Impact Analysis on Next-Generation Sequencing Market
7. Next-Generation Sequencing Market Analysis (Market Segmentation)
8. Next-Generation Sequencing Global Company Share Analysis – Key 3–5 Companies
9. Next-Generation Sequencing Company and Product Profiles
10. KOL Views
11. Project Approach
12. About DelveInsight
13. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com